Press coverage about Zoetis (NYSE:ZTS) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.8196789630085 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of research firms recently issued reports on ZTS. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. BidaskClub downgraded shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. BMO Capital Markets raised their price objective on shares of Zoetis to $78.00 and gave the stock a “market perform” rating in a report on Tuesday. Craig Hallum restated a “buy” rating and set a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $71.28.

Shares of Zoetis (NYSE:ZTS) traded up $0.87 during trading hours on Tuesday, reaching $75.11. 2,721,946 shares of the company’s stock were exchanged, compared to its average volume of 2,586,233. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The company has a market capitalization of $36,600.00, a price-to-earnings ratio of 39.53, a PEG ratio of 1.91 and a beta of 1.06. Zoetis has a 12-month low of $52.00 and a 12-month high of $75.47.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $0.52 earnings per share. sell-side analysts expect that Zoetis will post 2.37 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is currently 22.11%.

WARNING: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.